Welcome to our dedicated page for Black Diamond Therapeutics news (Ticker: BDTX), a resource for investors and traders seeking the latest updates and insights on Black Diamond Therapeutics stock.
Black Diamond Therapeutics, Inc. (BDTX) is a clinical-stage biotech company advancing tumor-agnostic therapies targeting oncogenic mutations in cancers like NSCLC and glioblastoma. This page provides investors and researchers with essential updates on the company’s precision oncology developments.
Find consolidated access to press releases, clinical trial data, and regulatory milestones for BDTX’s pipeline, including MasterKey therapies BDTX-1535 (EGFR inhibitor) and BDTX-4933. Track progress on mutation-targeted approaches addressing resistance mechanisms like the C797S mutation in EGFR.
Our news collection serves as a reliable resource for monitoring strategic partnerships, research publications, and FDA communications related to the company’s Mutation-Allostery-Pharmacology platform. Content is curated to help stakeholders assess scientific progress without promotional bias.
Bookmark this page for streamlined updates on Black Diamond’s efforts to expand treatment options in precision oncology. Check regularly for new developments in small-molecule kinase inhibitors and tumor-agnostic therapeutic strategies.
Black Diamond Therapeutics (Nasdaq: BDTX) reported promising pre-clinical results for its lead candidate, BDTX-189, at the 32nd EORTC-NCI-AACR Virtual Symposium. The data indicate BDTX-189 can inhibit allosteric EGFR and HER2 mutations while sparing wild-type EGFR, potentially reducing toxicity. BDTX-189 showed effective tumor regression in various models, including patient-derived xenografts. The candidate is advancing to Phase 1/2 clinical trials (MasterKey-01) in patients with advanced solid tumors. BDTX-189 has received Fast Track designation from the FDA for specific mutations in solid tumors.
Black Diamond Therapeutics (Nasdaq: BDTX) announced the presentation of pre-clinical data for its lead candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium on Molecular Targets and Cancer Therapeutics on October 25, 2020. BDTX-189 is designed as an irreversible small molecule inhibitor targeting oncogenic mutations in EGFR and HER2. This presentation may offer insights into treating genetically defined cancers, as no FDA-approved therapies currently exist for these specific mutations. The findings could represent a significant advancement in precision oncology.
Black Diamond Therapeutics (Nasdaq: BDTX) has announced the appointment of Robert A. Ingram as Chairman of its Board of Directors, succeeding founding Chairman Brad Bolzon, who will remain on the board. Ingram, a seasoned leader in the pharmaceutical industry with experience at GlaxoWellcome and GlaxoSmithKline, is expected to steer the company towards its goal of advancing precision oncology therapies. Black Diamond possesses a proprietary MAP platform aimed at targeting genetically defined cancers. The company is committed to transforming the oncology landscape through innovative small molecule therapies.
Black Diamond Therapeutics has appointed Robert A. Ingram as Chairman of its Board of Directors, effective immediately. Ingram, a notable figure in the pharmaceutical industry, previously served as CEO and Chairman of GlaxoWellcome and played a key role in forming GlaxoSmithKline. His experience is expected to bolster Black Diamond’s strategy in precision oncology, particularly in developing tumor-agnostic therapies. The company's MAP platform aims to identify and treat genetically defined cancers.
Black Diamond Therapeutics, a precision oncology company, announced that its CEO, David M. Epstein, Ph.D., will present at the Morgan Stanley 18th Annual Global Healthcare Conference on September 15, 2020, at 2:45 PM ET. The presentation aims to update on the company’s progress in developing small molecule, tumor-agnostic therapies for genetically defined cancers. A live webcast will be available on their investor relations website, with a replay accessible for three weeks. Black Diamond employs a proprietary MAP platform to target undrugged mutations in cancer.
Black Diamond Therapeutics announced the appointment of Rachel Humphrey, M.D. as Chief Medical Officer, effective immediately. Dr. Humphrey succeeds Karsten Witt, M.D., who will now serve as Senior Vice President of Non-Clinical Development. With extensive experience in oncology drug development, Dr. Humphrey joins from CytomX Therapeutics and has held senior roles at major pharmaceutical companies. Her leadership is expected to enhance the development of BDTX-189, an innovative inhibitor targeting oncogenic mutations across various cancers, which currently lacks a comparable FDA-approved treatment.
Black Diamond Therapeutics (BDTX) announced significant advancements regarding its lead candidate, BDTX-189, receiving FDA Fast Track designation for treating adult patients with specific solid tumors. The Phase 1/2 clinical trial is progressing as scheduled, with completion expected by mid-2021. Financially, the company reported a strong cash position of $345.0 million as of June 30, 2020, up from $39.7 million in Q2 2019. R&D expenses rose to $10.2 million, influenced by the trial's development, while G&A expenses also increased to $4.9 million.
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a leader in precision oncology, announced that CEO David M. Epstein will present at two upcoming investor conferences. The presentations are scheduled for August 12, 2020, at the Wedbush PacGrow Healthcare Conference and August 13, 2020, at the Canaccord Genuity Growth Conference. Live webcasts will be available on the company’s website, with replays archived for three weeks. Black Diamond focuses on developing tumor-agnostic therapies targeting undrugged mutations in genetically defined cancers.
Black Diamond Therapeutics (Nasdaq: BDTX) has appointed Fang Ni, Pharm.D., as Chief Business Officer. Ni, who has previously served as interim CBO and possesses extensive expertise in business development, is expected to lead strategic initiatives to advance the company’s clinical pipeline. He is credited with contributions to Black Diamond's corporate strategies and has a solid background in oncology from his tenure at Roche and Versant Ventures. The leadership change is aimed at capitalizing on Black Diamond's innovative MAP platform for drug discovery.
Black Diamond Therapeutics (Nasdaq: BDTX) announced FDA's Fast Track designation for BDTX-189, targeting adult patients with solid tumors harboring specific mutations. This designation aims to expedite the development of BDTX-189, an orally available small molecule inhibitor, which addresses unmet needs in cancer therapy. The drug is currently undergoing evaluation in the MasterKey-01 Phase 1/2 clinical trial, assessing its safety and effectiveness in patients with advanced solid tumors. The Fast Track status allows for closer collaboration with the FDA and a potential accelerated approval process.
FAQ
What is the current stock price of Black Diamond Therapeutics (BDTX)?
What is the market cap of Black Diamond Therapeutics (BDTX)?
